BRAF and metastatic melanoma: Earlier trials using BRAF inhibitor monotherapy showed limited activity [137]; therefore, more recently clinical trials have focused on BRAF–MEK inhibitor combination therapy, following superior outcomes in other malignancies such as metastatic melanoma for patients with BRAFV600E mutations [138,139].